PMID: 9435227Jan 22, 1998Paper

A double-headed Gly-Pro-Arg-Pro ligand mimics the functions of the E domain of fibrin for promoting the end-to-end crosslinking of gamma chains by factor XIIIa

Proceedings of the National Academy of Sciences of the United States of America
L LorandS N Murthy

Abstract

The E domain of fibrinogen represents the central region of the protein that, after the removal of fibrinopeptides from the N-termini of its alpha chains by thrombin, orders the noncovalent assembly of fibrin units into a half-staggered array. This structural organization is accomplished purely through noncovalent binding between the E domain of one molecule and the distal D domains of two others. The process of assembly has a physiologically important up-regulatory effect on the next enzymatic phase of blood coagulation, which is the factor XIIIa-catalyzed end-to-end ligation of the gamma chains at the D domains of the protein. Fibrin assembly, as well as the acceleration of the factor XIIIa reaction, could be prevented by Gly-Pro-Arg-Pro, a homologue of the natural sequence of amino acids at the N termini of alpha chains in the E domain. We have now succeeded with a simple double-headed ligand, bis(Gly-Pro-Arg-Pro-amido)polyethylene glycol, in fully replacing the regulatory functions of the large E domains of the native protein.

References

Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K Yamazumi, R F Doolittle
Sep 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·L LorandI Simpson
Dec 8, 1972·Annals of the New York Academy of Sciences·L LorandA Gray
Jun 27, 1983·Annals of the New York Academy of Sciences·R F Doolittle
Jun 27, 1983·Annals of the New York Academy of Sciences·C CohenE Daub
Jun 27, 1983·Annals of the New York Academy of Sciences·A HenschenC Southan
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·S A Olexa, A Z Budzynski
Feb 15, 1996·Structure·A K Freund
Apr 11, 1997·The Journal of Biological Chemistry·K N ParameswaranL Lorand
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·K P PrattE W Davie
Oct 1, 1952·The Biochemical Journal·L LORAND, W R MIDDLEBROOK
Oct 1, 1952·The Biochemical Journal·L LORAND
Jan 25, 1959·The Journal of Biophysical and Biochemical Cytology·C E HALL, H S SLAYTER
Aug 1, 1963·Archives of Biochemistry and Biophysics·L LORANDS K RIGGS
Oct 21, 1950·Nature·L LORAND
Feb 10, 1951·Nature·K BAILEYW R MIDDLEBROOK
Sep 10, 1948·Science·K Laki, L Lóránd

❮ Previous
Next ❯

Citations

Jan 23, 1999·Current Opinion in Structural Biology·R F DoolittleS J Everse
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y VeklichJ W Weisel
Sep 2, 1998·Proceedings of the National Academy of Sciences of the United States of America·M W MosessonJ F Hainfeld
Jan 5, 2000·Proceedings of the National Academy of Sciences of the United States of America·S N MurthyL Lorand
Jun 28, 2005·Journal of Thrombosis and Haemostasis : JTH·L Lorand
Mar 11, 2004·Journal of Thrombosis and Haemostasis : JTH·J W Weisel
Dec 21, 2005·Archives of Biochemistry and Biophysics·Muriel C MaurerBrian T Turner
Jul 27, 2000·The Journal of Biological Chemistry·M MoaddelD H Farrell
Jul 20, 2001·Annals of the New York Academy of Sciences·K C LounesS T Lord
Jun 28, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G PelusoM Calvani
Jul 20, 2001·Annals of the New York Academy of Sciences·L Lorand
Mar 25, 2015·Bioconjugate Chemistry·Leslie W ChanSuzie H Pun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.